2/3
11:28 pm
inkt
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]
2/3
09:30 pm
inkt
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
Medium
Report
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
1/19
01:06 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Low
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
1/11
01:03 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
1/8
12:00 pm
inkt
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
Low
Report
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
1/3
01:08 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
12/20
01:30 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
12/6
01:36 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Low
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
11/20
11:42 am
inkt
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
Medium
Report
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
11/14
07:08 pm
inkt
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation [Yahoo! Finance]
11/14
07:30 am
inkt
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
Low
Report
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation